Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin asset

May 15, 2026 10:22 AM EDT News Briefing Aard­vark's next move af­ter clin­i­cal hold; Alu­mis' ver­dict on Ace­lyrin as­set ENDPOINTS Plus, news about Tenaya’s TN-401 and Tai­ho’s In­qovi. 📉 Aard­vark to un­blind rare dis­ease tri­al fol­low­ing clin­i­cal hold: The FDA has Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER